OCU 300

Drug Profile

OCU 300

Alternative Names: OCU300

Latest Information Update: 27 Feb 2016

Price : $50

At a glance

  • Originator University of Illinois at Chicago
  • Developer Ocugen
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Graft-versus-host disease

Most Recent Events

  • 11 Feb 2016 Phase-II/III clinical trials in Ocular Graft-versus-host disease in USA (unspecified route)
  • 11 Feb 2016 OCU 300 licensed to Ocugen, from University of Illinois, worldwide
  • 11 Feb 2016 Ocugen plans a phase III trial for Dry eyes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top